Endocyte, Inc. Common Stock
ECYT
ECYT was delisted on the 20th of December, 2018.
75 hedge funds and large institutions have $18.4M invested in Endocyte, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 16 increasing their positions, 28 reducing their positions, and 22 closing their positions.
9% less funds holding
Funds holding: 82 → 75 (-7)
32% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 22
43% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 28
49% less capital invested
Capital invested by funds: $35.8M → $18.4M (-$17.4M)
68% less call options, than puts
Call options by funds: $147K | Put options by funds: $457K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$950K |
| 2 |
Millennium Management
New York
|
+$927K |
| 3 |
Goldman Sachs
New York
|
+$846K |
| 4 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$411K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$390K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.55M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.34M |
| 3 |
JP Morgan Chase
New York
|
-$791K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$681K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$650K |
ECYT Hedge Fund Activity: Q2 2017 in Review
75 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q2 2017, worth a combined $18.4M — down 49% from $35.8M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ECYT and 15 opened new positions — a net loss of 7 holders — while 28 trimmed existing stakes and 16 added.
The largest buyer was Morgan Stanley, adding an estimated $950K. The largest seller was BlackRock, cutting an estimated $3.55M.
- 75 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q2 2017, down from 82 in Q1 2017.
- Funds reported $18.4M of Endocyte, Inc. Common Stock stock for Q2 2017, down 49% quarter-over-quarter.
- 15 funds opened new Endocyte, Inc. Common Stock positions in Q2 2017 and 22 closed out, a net change of -7 holders.
- The largest Endocyte, Inc. Common Stock buyer in Q2 2017 was Morgan Stanley, an estimated $950K added.
- The largest Endocyte, Inc. Common Stock seller in Q2 2017 was BlackRock, an estimated $3.55M sold.
Based on aggregated 13F filings for Q2 2017.